Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 125 publications
Associations Between Pigmentation and the Clinicopathologic and Immune Landscape of Melanoma.
Journal: The American Journal of dermatopathology
Published: March 20, 2026
Immunologic determinants of infusion products and the tumor microenvironment govern response to TIL therapy in advanced melanoma.
Journal: Med (New York, N.Y.)
Published: March 17, 2026
Correction: BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling.
Journal: eLife
Published: February 19, 2026
Driver mutations and tumor mutational burden impact stage IV melanoma survival.
Journal: Journal of the American Academy of Dermatology
Published: February 11, 2026
Neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma: an investigator-initiated, open-label phase II trial.
Journal: Journal for immunotherapy of cancer
Published: December 16, 2025
ASO Visual Abstract: Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative or Not Performed Sentinel Lymph Node Biopsy.
Journal: Annals of surgical oncology
Published: December 08, 2025
Response to Gao and Chen, "Comments on Akaike et al's 'Circulating tumor DNA level is associated with time to clinical recurrence in Merkel cell carcinoma: Implications for patient management'".
Journal: Journal of the American Academy of Dermatology
Published: November 24, 2025
ASO Author Reflections: Merkel Cell Carcinoma and Nodal Staging with SLNB.
Journal: Annals of surgical oncology
Published: October 27, 2025
Phase I study of ABM-1310 as monotherapy and in combination with cobimetinib for BRAF-mutated advanced solid tumors: safety, efficacy, and dose expansion.
Journal: ESMO open
Published: October 03, 2025
Case Report: Durable response to tumor-infiltrating lymphocyte therapy in a patient with metastatic melanoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.
Journal: Frontiers in immunology
Published: October 03, 2025
First-line ipilimumab plus nivolumab in advanced merkel cell carcinoma: a meta-analysis of prospective trials and real-world validation cohort.
Journal: Cancer immunology, immunotherapy : CII
Published: September 15, 2025
Summary recommendations from the NCI clinical trials planning meeting (CTPM) on advanced cutaneous squamous cell carcinoma in immunosuppressed patients.
Journal: Journal of the National Cancer Institute
Published: August 05, 2025
Last Updated: 09/26/2026